Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It all depends if no offering comes in tomorrow.
I am thinking MUCH higher....
This should easily pass $10.00 tomorrow. Also watch SFET.
Congrats to you big time!
Shares of Akari Therapeutics PLC (AKTX) toward a 15-month high in very active Wednesday, enough to pace all the gainers on the Nasdaq exchange, after the company said it plans to commence trials in European and U.S. pediatric patients this year for its treatment of pediatric thrombotic microangiopathy. Trading volume rocketed to 22.3 million shares, compared with the full-day average of about 20,000 shares. The company said it had a "successful," pre-investigational new drug (IND) meeting with the Food and Drug Administration regarding its pivotal clinical trial program for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), which is an orphan condition with an estimated fatality rate of 80%. Chief Executive Clive Richardson said trials in HSCT-TMA patients are planned to begin in the fourth quarter. "We see HSCT-TMA as a gateway indication into a range of other poorly treated orphan TMAs, and are enthusiastic about the potential of Coversin to offer an improved standard of care for patients with these rare and usually fatal conditions," Richardson said. The stock has now run up 93% over the past 12 months, while the iShares Nasdaq Biotechnology ETF (IBB) has slipped 1.1% and the S&P 500 gained 0.9%.
-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
Copyright (c) 2019 Dow Jones & Company, Inc.
SFET and this AKTX are the main watcher for tomorrow.
Also watch SFET that should hit $4.00 tomorrow.
AKTX HERE COMES $7
Lots of buying STILL going on after hours. This may get CRAZY tomorrow!!!
Chit that market cap is nothing compared to the news, talk about a market cap of at least 300 million dollars.
And the year was in 2015
Indeed it closed way HOD
6.50 is 100 mil market cap wonder what it does tommorow
might have to buy back in
* * $AKTX Video Chart 03-13-2019 * *
Link to Video - click here to watch the technical chart video
It's not, I was in AQXP from 1.64 for 4000 shares the same day it climbed all the way to 13.50 my stop was set at 10.50 it got triggered and watch go as high as 52 dollars the next day, the news was only a phase 2, this news is far better.
Hmm man far reach but i would be so fuking happy
Huge day tomorrow. Price target changed to $20.00 tomorrow.
All the walls will be annihilated come tomorrow morning. No ifs or but and heading for $10.00 plus tomorrow.
Bought these at 3.70 and not selling a damn single share of 1400 of shares until we hit $10.00 tomorrow.
AKTX!! Thank you sweetie!! BEAST MODE!! HUUUUGE GAPPER TOMORROW!!! MBD
No slowing this train down. Wow no where near over.Do not sell all your shares.
bs naked shorters
should be illegal but this the rules of dumb game we play in
7 would have been possible without the trading haults
Strap in for POWER HOUR Boys!!!!!!!! 5 mins till lift off. To much strength here for any pull back not to be crushed!
So they have an open share registration could be diluting today. Huge volume. Market absorbing very well! Let er ride!
i did flip this from 4.8 to 5.2 though heheh
once u see the red n green flashing chrtistmas light high frequency robot trades...
its time to get out
5$ stox always get shorted back to 4 they got infinite money to do it.
thats why i stear clear of 5$ stox better to buy 2$-3$ or .05
AKTX a beast!!!! THOSE who didn't get in early here, here is the next runner!! Do your DD fast!!!
TLGT now under the radar, but not for long! TLGT is the next AKTX/BPTH IMO!!! Check it out!! Get in early and be patient!!! 82.75% held by institutions!!! MBD
Interactive Brokers has no shares for retail to short. And big players are paying a serious premium to borrow they told me.
If the bulls get really aggressive here today. Who knows what happens.
But always have to be on the look put with these to do a shelf offer at the close today. If no shelf boom!
Thanks been banking but still trading and holding a nice free stack.GLTU this party not over here!
And boom there it is.Holding a stack for 15.00 pps
I am out at $5.78. I do agree they could run it hard again tomorrow but the crazy fast swings today made me dizzy all day long. GL.
This is why I have a margin account. Trade it till your fingers are sore. Wow what a day and its not even over!
Very nice. Congrats and AMEN!!
AKTX!! Hey my buddy Braze!! This was a hard one to endure...glad we made it!!!! Blessings to you and your family!!!! MBD
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
554
|
Created
|
09/21/15
|
Type
|
Free
|
Moderators |
Akari is focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, and leukotriene system,
for the treatment of rare and orphan diseases with unmet need. We believe that blocking early mediators of inflammation
will prevent initiation and continual amplification of the processes that cause certain diseases.
Nomacopan is a recombinant small protein (16,740 Da) that acts on complement component-C5,
preventing release of C5a and formation of C5b–9 (also known as the membrane attack complex, or MAC),
and independently also inhibits leukotriene B4, or LTB4, activity, both elements that are co-located as part of the immune/inflammatory response.
Nomacopan is currently being clinically evaluated in four indications:
Akari believes that the dual action of nomacopan on both C5 and LTB4 may be beneficial in AKC, BP, and aHUS. Akari is also developing other tick derived proteins, including longer acting versions.
Nomacopan is a highly soluble and stable biological molecule, and independently binds to both C5 and LTB4. This novel dual binding enables targeting of two distinct and separate disease categories based on their underlying etiology.
July 1, 2020
July 1, 2020
June 1, 2020
May 1, 2020
March 31, 2020
Patients with COVID-19 pneumonia
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |